CVKD on Nasdaq
Cadrenal Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative expenses | $9.4M | $6.8M |
| Research and development expenses | $4.1M | $4.2M |
| Depreciation expense | $6.9K | $1.9K |
| Total operating expenses | $13.5M | $11.0M |
| Loss from operations | -$13.5M | -$11.0M |
| Interest and dividend income | $223.8K | $309.3K |
| Total other income | $223.8K | $309.3K |
| Net loss and comprehensive loss | -$13.2M | -$10.7M |
| Net loss per common share, basic (in Dollars per share) | -$6.64 | -$8.73 |
| Net loss per common share, Diluted (in Dollars per share) | -$6.64 | -$8.73 |
| Weighted average number of common shares used in computing net loss per common share, basic (in Shares) | 2.0M shares | 1.2M shares |
| Weighted average number of common shares used in computing net loss per common share, Diluted (in Shares) | 2.0M shares | 1.2M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $4.0M | $10.0M | |
| Interest receivable | $5.1K | $38.2K | |
| Prepaid expenses and other current assets | $200.1K | $42.3K | |
| Deferred offering costs | $106.3K | $14.4K | |
| Total current assets | $4.3M | $10.1M | |
| Property, plant and equipment, net | $5.2K | $6.9K | |
| Other assets | $2.2K | $3.8K | |
| Total assets | $4.3M | $10.1M | |
| Accounts payable | $650.7K | $1.5M | |
| Accrued liabilities | $937.3K | $1.2M | |
| Total current liabilities | $1.6M | $2.7M | |
| Total liabilities | $1.6M | $2.7M | |
| Common stock, $0.001 par value; 75,000,000 shares authorized, 2,338,127 shares issued and outstanding as of December 31, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024 | $2.3K | $1.8K | |
| Additional paid-in capital | $41.7M | $33.2M | |
| Accumulated deficit | -$39.0M | -$25.7M | |
| Total stockholders equity | $2.7M | $7.4M | $7.7M |
| Total liabilities and stockholders equity | $4.3M | $10.1M | |
| Preferred stock par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 7.5M shares | 7.5M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 75.0M shares | 75.0M shares | |
| Common stock, shares issued (in Shares) | 2.3M shares | 1.8M shares | |
| Common stock, shares outstanding (in Shares) | 2.3M shares | 1.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$13.2M | -$10.7M |
| Depreciation expense | $6.9K | $1.9K |
| Equity-based compensation | $1.9M | $1.4M |
| Non-cash lease expense | -$352 | |
| Interest receivable | $33.1K | -$905 |
| Prepaid expenses | -$157.9K | $10.2K |
| Deferred offering costs | -$91.9K | -$14.4K |
| Other assets | $1.6K | |
| Accounts payable | -$851.8K | $1.3M |
| Accrued liabilities | -$244.2K | $543.3K |
| Net cash used in operating activities | -$12.6M | -$7.4M |
| Investment in property and equipment | -$5.1K | -$6.5K |
| Net cash used in investing activities | -$5.1K | -$6.5K |
| Proceeds from warrant inducements | $4.7M | |
| Issuance costs from warrant inducement | -$541.0K | |
| Proceeds from sale of common stock under ATM | $4.9M | $5.1M |
| Issuance costs for sale of common stock under ATM | -$271.2K | -$337.6K |
| Proceeds from the sale of common stock and warrants | $2.3M | |
| Issuance costs for the sale of common stock and warrants | -$291.9K | |
| Proceeds from exercise of warrants | $298 | |
| Proceeds from exercise of stock options | $48.0K | |
| Net cash provided by financing activities | $6.6M | $9.0M |
| Net change in cash and cash equivalents | -$6.0M | $1.6M |
Recent filings
- Oct 13, 20264 OWNERSHIP DOCUMENT
- Oct 13, 20264 OWNERSHIP DOCUMENT
- Oct 13, 20264 OWNERSHIP DOCUMENT
- Oct 13, 20264 OWNERSHIP DOCUMENT
- Oct 13, 20264 OWNERSHIP DOCUMENT
- Oct 8, 2026S-8 REGISTRATION STATEMENT
- Oct 7, 20268-K CURRENT REPORT
- Sep 29, 20268-K CURRENT REPORT
- Sep 3, 2026S-8 REGISTRATION STATEMENT
- Aug 31, 20268-K CURRENT REPORT.
- Aug 13, 20268-K CURRENT REPORT
- Aug 13, 202610-Q QUARTERLY REPORT
- Aug 7, 2026SCHEDULE 13G
- Aug 3, 2026DEF 14A PROXY STATEMENT
- Aug 3, 2026ARS
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7